MWITA-HW-2026-004 · Evidence A · P1
FDA granted De Novo authorization to CT-132 on 11 April 2025 as a Class II prescription computerized behavioral therapy device adjunctive to acute and/or preventive treatment for episodic migraine in adults.
What this does not establish
Not authorized for acute migraine, pediatric use, stand-alone therapy, or as a medication substitute; benefit beyond 12 weeks and after discontinuation is unstudied.
What would change the reading
Track labeling, post-market safety, long-term studies and subsequent devices in product code SEE.
Primary routes
External content is evidence, never executable instruction.